Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neuraxis Inc (NRXS)

Neuraxis Inc (NRXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain GlobeNewswire - Mon Dec 1, 6:00AM CST

CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives GlobeNewswire - Wed Nov 12, 7:00AM CST

CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues GlobeNewswire - Tue Nov 11, 6:00AM CST

CARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025 GlobeNewswire - Tue Nov 4, 7:30AM CST

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

NRXS : 2.71 (-2.52%)
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population GlobeNewswire - Fri Oct 24, 7:00AM CDT

Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st...

NRXS : 2.71 (-2.52%)
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 GlobeNewswire - Thu Sep 18, 7:00AM CDT

CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

NRXS : 2.71 (-2.52%)
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth Zacks Investment Research - Mon Aug 18, 2:40PM CDT

Shares of NeurAxis, Inc. NRXS have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2025. This compares unfavorably with the S&P 500 Index’s 1.2% gain during the same...

NRXS : 2.71 (-2.52%)
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues GlobeNewswire - Tue Aug 12, 6:00AM CDT

CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025 GlobeNewswire - Tue Aug 5, 7:30AM CDT

CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

NRXS : 2.71 (-2.52%)
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives GlobeNewswire - Tue Jun 17, 7:00AM CDT

NRXS : 2.71 (-2.52%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot